PHASE II TRIAL OF SECOND-LINE ERLOTINIB AND DIGOXIN FOR NONSMALL CELL LUNG CANCER (NSCLC)



Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions

Bronchiolitis obliterans syndrome (BOS) may develop after either lung or haematopoietic stem cell transplantation (HSCT), with similarities in histopathological features and clinical manifestations.However, there are differences in the contributory factors and clinical trajectories between the two conditions.BOS after HSCT occurs due to systemic gr

read more